<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63450">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02279888</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-10035</org_study_id>
    <nct_id>NCT02279888</nct_id>
  </id_info>
  <brief_title>CardioMEMS HF System Post Approval Study</brief_title>
  <official_title>CardioMEMS HF System Post Approval Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the CardioMEMS HF System Post Approval Study (PAS) is to evaluate the use of
      the CardioMEMS HF System in patients with NYHA class III heart failure in a commercial
      setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>freedom from device/system related complication</measure>
    <time_frame>two year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>freedom from pressure sensor failure</measure>
    <time_frame>two year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>heart failure hospitalization rate</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>heart failure hospitalization or death rate</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Heart Failure</condition>
  <condition>Left-Sided Heart Failure</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>CardioMEMS HF System Group</arm_group_label>
    <description>Patients implanted with a CardioMEMS HF System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CardioMEMS HF System</intervention_name>
    <description>Pulmonary artery pressure sensor</description>
    <arm_group_label>CardioMEMS HF System Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with NYHA class III heart failure
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of NYHA class III heart failure

          -  At least 1 heart failure hospitalization within previous 12 months

          -  Patients with reduced LVEF heart failure should be receiving a beta blocker for 3
             months and an ACE-I or ARB for one month unless in the investigator's opinion, the
             patient is intolerant to beta blockers, ACE-I or ARB

          -  BMI ≤ 35. Patients with BMI &gt;35 will require their chest circumference to be measured
             at the axillary level. If &gt; 65 inches the patient will not be eligible for the study.

          -  Pulmonary artery branch diameter ≥ 7mm - (implant target artery - assessed during the
             right heart catheterization)

        Exclusion Criteria:

          -  Active infection

          -  History of recurrent (&gt; 1) pulmonary embolism or deep vein thrombosis

          -  Inability to tolerate a right heart catheterization

          -  A major cardiovascular event (e.g., myocardial infarction, open heart surgery,
             stroke, etc.) within previous 2 months

          -  Cardiac resynchronization device (CRT) implanted within previous 3 months

          -  Glomerular Filtration Rate (GFR) &lt; 25 ml/min (obtained within 2 weeks of implant) who
             are non-responsive to diuretic therapy or who are on chronic renal dialysis

          -  Congenital heart disease or mechanical right heart valve

          -  Likely to undergo heart transplantation or VAD within the next 6 months

          -  Known coagulation disorders

          -  Hypersensitivity or allergy to aspirin, and/or clopidogrel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynne Stevenson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Neville</last_name>
    <phone>678-651-2326</phone>
    <email>sneville@sjm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West Virginia Heart Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annina Mendell, RN</last_name>
      <phone>304-293-0615</phone>
      <email>mendella@wvuhealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Robert Hull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 6, 2016</lastchanged_date>
  <firstreceived_date>October 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Artery Pressure Monitoring</keyword>
  <keyword>Implantable Hemodynamic Monitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
